Torrance, CA (September 26, 2011) - Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, announces the addition of a Phenyl-Hexyl phase to its successful Kinetex core-shell HPLC/UHPLC column family. Kinetex Phenyl-Hexyl offers a unique selectivity for the separation of compounds that are difficult to resolve using traditional phenyl phases. The new Phenyl-Hexyl columns complement the existing Kinetex phases and are especially effective for resolving aromatic hydrocarbons such as tricyclic antidepressants and explosives. Like C18, Phenyl-Hexyl is ideal for a wide range of applications, including the resolution of moderate hydrophobic compounds.
The Kinetex Phenyl-Hexyl is offered in 2.6- and 1.7-micron particle sizes. “The addition of a Phenyl-Hexyl phase to the Kinetex core-shell line of HPLC/UHPLC columns gives chromatographers one of the most useful selectivities on one of the most advanced LC technologies,” explains Jeremy Bierman, brand manager for Phenomenex.
With complementary C18 and Phenyl phases, users can screen for optimal resolution of complex sample mixtures. Bierman adds, “With the addition of this unique selectivity to our successful portfolio of reversed phase chemistries on core-shell HPLC and UHPLC media, we now address the vast majority of separation needs in the industry.”
Kinetex core-shell technology meets researchers’ need to improve results and increase productivity without large capital expenditures. The new Phenyl-Hexyl offering brings the total number of Kinetex phases to six, and the company plans to continue expanding the choices.
Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical, government and academic laboratories. From drug discovery and pharmaceutical development to disease diagnosis, food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being.
For more information on Phenomenex, visit www.phenomenex.com
